Know Labs, INC

USBC, Inc. has drawn an additional $3.0 million under its Master Loan Agreement and continues to progress with its tokenized deposit product development and pilot programs.

USBC, Inc. has drawn an additional $5.0 million under its Master Loan Agreement, bringing the total outstanding to $15.0 million, while continuing development and testing of its tokenized deposit product with Vast Bank.

USBC, Inc. has filed an 8-K detailing the departure of Ronald P. Erickson from his roles as Director and President of the Science Division, along with the terms of his separation agreement.

USBC, Inc. has completed the divestiture of its legacy non-invasive sensor technology business to a company controlled by former CEO Ron Erickson to prioritize its tokenized deposit platform.

USBC, Inc. announced it has regained full compliance with NYSE American continued listing standards, resolving previous minimum stockholders equity deficiencies.

USBC, Inc. announced the repricing of 83 million outstanding stock options to an exercise price of $0.37 per share to motivate and retain key personnel.

USBC, Inc. reported a net loss of $25.6 million for Q1 2026, significantly impacted by digital asset valuation changes and increased operating expenses related to its tokenized deposit program development.

Know Labs, Inc. reports significant losses and a working capital deficit, raising substantial doubt about its ability to continue as a going concern, despite efforts to secure new capital and reduce operating expenses.

Know Labs reports a net loss of $3.58 million for Q2 2025 and expresses substantial doubt about its ability to continue as a going concern.

Know Labs, Inc. reports a net loss for Q1 2025 while advancing its non-invasive diagnostic technology and launching a technology licensing program.

Know Labs, Inc. released its Q3 2024 financial results, highlighting ongoing development of its non-invasive glucose monitoring technology and recent capital raising activities.

Know Labs, Inc. released its first quarter 2024 financial results, showcasing advancements in its non-invasive glucose monitoring technology and ongoing efforts to secure FDA clearance.

USBC, Inc. has filed an amendment to its Transition Report on Form 10-K for the period ending December 31, 2025, primarily to include Part III information.

USBC Inc. reported a significant net loss driven by Bitcoin price volatility while advancing its tokenized deposit initiative and securing a new $25 million loan facility.

USBC, Inc. has completed a strategic pivot to digital financial technologies, including a Bitcoin treasury strategy and tokenized deposit offering, following a $125 million controlling-interest acquisition.

Know Labs, Inc. filed an amendment to its annual report on Form 10-K to include the consent of its independent auditor, BPM LLP, which was inadvertently omitted from the original filing.

Know Labs, a developer of non-invasive medical diagnostics, reported significant progress in its development of a non-invasive glucose monitoring device, but faces financial challenges and ongoing operating losses.

USBC, Inc. director Linda Jenkinson's stock options for 10 million shares were repriced from $1.10 to $0.37 per share under the 2021 Equity Incentive Plan.

USBC, Inc. CFO Kitty B. Payne's stock options for 3.75 million shares were repriced from $1.10 to $0.37 per share.

USBC, Inc. CFO Kitty B. Payne saw 1.79 million stock options repriced to $1.10 and received a new grant of 1.96 million options, totaling 3.75 million beneficially owned.

USBC Director Linda Jenkinson saw 4.76 million stock options repriced to $1.10 and received a new grant of 5.24 million options, totaling 10 million beneficially owned.

USBC, Inc.'s Chief Operating Officer, Kirk Chapman, received a repricing of 7.14 million stock options to $1.10 per share and a new grant of 7.86 million options at the same price.

USBC, Inc. Director Linda Jenkinson received a grant of options to purchase 4.76 million shares of common stock under the company's 2021 Equity Incentive Plan.

USBC, Inc. announces a $125 million capital investment and the launch of its innovative U.S. dollar-denominated, identity-embedded, blockchain-based deposit token, ahead of its 2025 Annual Stockholders Meeting.

Know Labs, Inc. has adjourned its Special Shareholder Meeting to July 31, 2025, urging stockholders to vote FOR all proposals before the July 30, 2025 deadline.

Know Labs, Inc. has engaged Laurel Hill Advisory Group, LLC to assist with proxy solicitation for its Special Meeting of Stockholders scheduled for July 31, 2025.

Know Labs, Inc. has adjourned its Special Meeting of Stockholders to July 31, 2025, to provide additional time for stockholders to vote on all proposals.

Know Labs, Inc. reminds stockholders to cast their votes for the upcoming Special Meeting on July 24, 2025, emphasizing the Board's unanimous recommendation for all proposals.

Know Labs, Inc. is calling a special shareholder meeting to approve a significant increase in authorized common stock, a private placement of up to $119.9 million, and an expansion of its equity incentive plan, all critical to avoid potential cessation of operations and bankruptcy.

USBC, Inc. has filed Amendment No. 4 to its Form S-1 Registration Statement, updating disclosures and adding exhibits related to its tokenized deposit offering and Bitcoin treasury strategy.

USBC, Inc. has filed an amendment to its S-1 registration statement, reducing the number of shares of common stock offered by selling stockholders and incorporating recent financial reports.

USBC, Inc. has filed an amendment to its registration statement to facilitate the resale of 367.6 million shares of common stock by existing stockholders.

USBC, Inc. files an amended S-1 registration statement for the resale of 367.6 million common shares by selling stockholders, including Goldeneye 1995 LLC, without receiving any proceeds.

USBC, Inc. files an S-1 registration statement to allow selling stockholders to resell 367.6 million common shares, following a major strategic pivot into digital assets and banking, including a Bitcoin treasury.

Know Labs is seeking to raise approximately $4.0 million through a public offering of units, each consisting of one share of common stock and one warrant, to further develop its non-invasive glucose monitoring technology.

Robert Gregory Kidd and Goldeneye 1995 LLC filed an amended Schedule 13D, revealing a Registration Rights Agreement for their 92.1% stake in USBC, Inc.

Robert Gregory Kidd and Goldeneye 1995 LLC have acquired a controlling 93.1% stake in Know Labs, Inc. through a private placement.

A significant shareholder, Clayton A. Struve, has reduced his beneficial ownership in Know Labs, Inc. below 5% following a private placement and debt conversion.

Ronald P. Erickson's beneficial ownership in Know Labs, Inc. has fallen to 0.7% following a private placement and Series H Preferred Stock redemption.

Ronald P. Erickson and affiliated entities, including J3E2A2Z Limited Partnership, have disclosed a 19.99% beneficial ownership stake in Know Labs, Inc., primarily through a recent conversion of $1.18 million in debt into Series H Preferred Stock.

Clayton A Struve has disclosed a 9.99% beneficial ownership stake in KNOW LABS, INC., primarily through convertible securities and warrants, following an increase in his beneficial ownership limitation.

Todd Baszucki has filed a Schedule 13G, revealing a passive beneficial ownership of 14% of KNOW LABS, INC.'s Common Stock.